Are drugs used to treat high-altitude sickness likely to be of any help against COVID-19?
Thursday, April 30, 2020
By William Boger
Copy link
Copy featured image
NO
Acetazolamide and nifedpine are commonly used to treat respiratory symptoms in patients suffering from high-altitude pulmonary edema when fluid begins to accumulate in the lungs. A Brooklyn doctor has suggested acetazolamide would be worth examining to see if it could treat similar lung problems observed in many COVID-19 patients.
A Seattle doctor who specialize in pulmonary diseases disagrees, warning against any "false equation" of the lung problems. Using acetazolamide for COVID patients "is just wrong," he has said. High-altitude sickness and COVID are "fundamentally different from each other." Medications used to treat altitude sickness could have dangerous consequences in COVID-19 patients, he warns.
This fact brief is responsive to conversations such as this one.
Sources
ABOUT THE CONTRIBUTOR
Between 2020 and 2022, under close editorial supervision, Gigafact contracted a group of freelance writers and editors to test the concepts for fact briefs and provide inputs to our software development process. We call this effort Gigafact Foundry. Over the course of these two years, Gigafact Foundry writers published over 1500 fact briefs in response to claims they found online. Their important work forms the basis of Gigafact formats and editorial guidelines, and is available to the public on Gigafact.org. Readers should be aware that while there is still a lot of relevant information to be found, not all fact briefs produced by Gigafact Foundry reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date and need to be looked at with fresh eyes, don't hesitate to contact us at support@gigafact.org.
FACT BRIEF BY
